EICHORCondition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Sponsor: Institute of Cancer Research, United Kingdom
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
PROMIZE Team · 02087224497 · PROMIZE@icr.ac.uk
Bindu Rao Baikady, PhD · +442034376033 · bindu.baikady@icr.ac.uk
Always discuss trial participation with your own doctor first.
| Oncolgy Institute of Southern Switzerland (IOSI) | Bellinzona, Switzerland | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06126731